Current practice and short-term outcomes of therapeutic mammaplasty in the international TeaM multicentre prospective cohort study

TeaM Steering Group

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND: Therapeutic mammaplasty, which combines breast reduction and mastopexy techniques with tumour excision, may extend the boundaries of breast-conserving surgery and improve outcomes for patients, but current practice is unknown and high-quality outcome data are lacking. This prospective multicentre cohort study aimed to explore the practice and short-term outcomes of the technique.

METHODS: Consecutive patients undergoing therapeutic mammaplasty at participating centres between 1 September 2016 and 30 June 2017 were recruited to the study. Demographic, preoperative, operative, oncological and complication data were collected. The primary outcome was unplanned reoperation for complications within 30 days of surgery. Secondary outcomes included re-excision rates and time to adjuvant therapy.

RESULTS: Overall, 880 patients underwent 899 therapeutic mammaplasty procedures at 50 centres. The most common indications were avoidance of poor cosmetic outcomes associated with standard breast-conserving surgery (702 procedures, 78·1 per cent) or avoidance of mastectomy (379, 42·2 per cent). Wise-pattern skin incisions were the most common (429 of 899, 47·7 per cent), but a range of incisions and nipple-areola pedicles were used. Immediate contralateral symmetrization was performed in one-third of cases (284 of 880, 32·3 per cent). In total, 205 patients (23·3 per cent) developed a complication, but only 25 (2·8 per cent) required reoperation. Median postoperative lesion size was 24·5 (i.q.r. 16-38) mm. Incomplete excision was seen in 132 procedures (14·7 per cent), but completion mastectomy was required for only 51 lesions (5·7 per cent). Median time to adjuvant therapy was 54 (i.q.r. 42-66) days.

CONCLUSION: Therapeutic mammaplasty is a safe and effective alternative to mastectomy or standard breast-conserving surgery. Further work is required to explore the impact of the technique on quality of life, and to establish cost-effectiveness.

Original languageEnglish
Pages (from-to)1778-1792
Number of pages15
JournalBritish Journal of Surgery
Volume105
Issue number13
Early online date22 Aug 2018
DOIs
Publication statusPublished - Dec 2018

Fingerprint

Mammaplasty
Cohort Studies
Prospective Studies
Segmental Mastectomy
Mastectomy
Nipples
Reoperation
Therapeutics
Cosmetics
Multicenter Studies
Cost-Benefit Analysis
Breast
Quality of Life
Demography
Skin
Neoplasms

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms/surgery
  • Carcinoma, Ductal, Breast/surgery
  • Clinical Decision-Making
  • Female
  • Humans
  • Italy
  • Mammaplasty/methods
  • Mastectomy/methods
  • Middle Aged
  • Patient Care Planning
  • Patient Readmission/statistics & numerical data
  • Perforator Flap/statistics & numerical data
  • Postoperative Complications/etiology
  • Practice Patterns, Physicians'/statistics & numerical data
  • Preoperative Care
  • Prospective Studies
  • Reoperation/statistics & numerical data
  • Treatment Outcome
  • United Kingdom
  • Young Adult

Cite this

Current practice and short-term outcomes of therapeutic mammaplasty in the international TeaM multicentre prospective cohort study. / TeaM Steering Group.

In: British Journal of Surgery, Vol. 105, No. 13, 12.2018, p. 1778-1792.

Research output: Contribution to journalArticle

@article{adb3b165564f4745b67bcd257d054223,
title = "Current practice and short-term outcomes of therapeutic mammaplasty in the international TeaM multicentre prospective cohort study",
abstract = "BACKGROUND: Therapeutic mammaplasty, which combines breast reduction and mastopexy techniques with tumour excision, may extend the boundaries of breast-conserving surgery and improve outcomes for patients, but current practice is unknown and high-quality outcome data are lacking. This prospective multicentre cohort study aimed to explore the practice and short-term outcomes of the technique.METHODS: Consecutive patients undergoing therapeutic mammaplasty at participating centres between 1 September 2016 and 30 June 2017 were recruited to the study. Demographic, preoperative, operative, oncological and complication data were collected. The primary outcome was unplanned reoperation for complications within 30 days of surgery. Secondary outcomes included re-excision rates and time to adjuvant therapy.RESULTS: Overall, 880 patients underwent 899 therapeutic mammaplasty procedures at 50 centres. The most common indications were avoidance of poor cosmetic outcomes associated with standard breast-conserving surgery (702 procedures, 78·1 per cent) or avoidance of mastectomy (379, 42·2 per cent). Wise-pattern skin incisions were the most common (429 of 899, 47·7 per cent), but a range of incisions and nipple-areola pedicles were used. Immediate contralateral symmetrization was performed in one-third of cases (284 of 880, 32·3 per cent). In total, 205 patients (23·3 per cent) developed a complication, but only 25 (2·8 per cent) required reoperation. Median postoperative lesion size was 24·5 (i.q.r. 16-38) mm. Incomplete excision was seen in 132 procedures (14·7 per cent), but completion mastectomy was required for only 51 lesions (5·7 per cent). Median time to adjuvant therapy was 54 (i.q.r. 42-66) days.CONCLUSION: Therapeutic mammaplasty is a safe and effective alternative to mastectomy or standard breast-conserving surgery. Further work is required to explore the impact of the technique on quality of life, and to establish cost-effectiveness.",
keywords = "Adult, Aged, Aged, 80 and over, Breast Neoplasms/surgery, Carcinoma, Ductal, Breast/surgery, Clinical Decision-Making, Female, Humans, Italy, Mammaplasty/methods, Mastectomy/methods, Middle Aged, Patient Care Planning, Patient Readmission/statistics & numerical data, Perforator Flap/statistics & numerical data, Postoperative Complications/etiology, Practice Patterns, Physicians'/statistics & numerical data, Preoperative Care, Prospective Studies, Reoperation/statistics & numerical data, Treatment Outcome, United Kingdom, Young Adult",
author = "O'Connell, {R L} and E Baker and A Trickey and T Rattay and L Whisker and Macmillan, {R D} and S Potter and Yazan Masannat and {TeaM Steering Group}",
note = "{\circledC} 2018 BJS Society Ltd Published by John Wiley & Sons Ltd.",
year = "2018",
month = "12",
doi = "10.1002/bjs.10959",
language = "English",
volume = "105",
pages = "1778--1792",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "British Journal of Surgery",
number = "13",

}

TY - JOUR

T1 - Current practice and short-term outcomes of therapeutic mammaplasty in the international TeaM multicentre prospective cohort study

AU - O'Connell, R L

AU - Baker, E

AU - Trickey, A

AU - Rattay, T

AU - Whisker, L

AU - Macmillan, R D

AU - Potter, S

AU - Masannat, Yazan

AU - TeaM Steering Group

N1 - © 2018 BJS Society Ltd Published by John Wiley & Sons Ltd.

PY - 2018/12

Y1 - 2018/12

N2 - BACKGROUND: Therapeutic mammaplasty, which combines breast reduction and mastopexy techniques with tumour excision, may extend the boundaries of breast-conserving surgery and improve outcomes for patients, but current practice is unknown and high-quality outcome data are lacking. This prospective multicentre cohort study aimed to explore the practice and short-term outcomes of the technique.METHODS: Consecutive patients undergoing therapeutic mammaplasty at participating centres between 1 September 2016 and 30 June 2017 were recruited to the study. Demographic, preoperative, operative, oncological and complication data were collected. The primary outcome was unplanned reoperation for complications within 30 days of surgery. Secondary outcomes included re-excision rates and time to adjuvant therapy.RESULTS: Overall, 880 patients underwent 899 therapeutic mammaplasty procedures at 50 centres. The most common indications were avoidance of poor cosmetic outcomes associated with standard breast-conserving surgery (702 procedures, 78·1 per cent) or avoidance of mastectomy (379, 42·2 per cent). Wise-pattern skin incisions were the most common (429 of 899, 47·7 per cent), but a range of incisions and nipple-areola pedicles were used. Immediate contralateral symmetrization was performed in one-third of cases (284 of 880, 32·3 per cent). In total, 205 patients (23·3 per cent) developed a complication, but only 25 (2·8 per cent) required reoperation. Median postoperative lesion size was 24·5 (i.q.r. 16-38) mm. Incomplete excision was seen in 132 procedures (14·7 per cent), but completion mastectomy was required for only 51 lesions (5·7 per cent). Median time to adjuvant therapy was 54 (i.q.r. 42-66) days.CONCLUSION: Therapeutic mammaplasty is a safe and effective alternative to mastectomy or standard breast-conserving surgery. Further work is required to explore the impact of the technique on quality of life, and to establish cost-effectiveness.

AB - BACKGROUND: Therapeutic mammaplasty, which combines breast reduction and mastopexy techniques with tumour excision, may extend the boundaries of breast-conserving surgery and improve outcomes for patients, but current practice is unknown and high-quality outcome data are lacking. This prospective multicentre cohort study aimed to explore the practice and short-term outcomes of the technique.METHODS: Consecutive patients undergoing therapeutic mammaplasty at participating centres between 1 September 2016 and 30 June 2017 were recruited to the study. Demographic, preoperative, operative, oncological and complication data were collected. The primary outcome was unplanned reoperation for complications within 30 days of surgery. Secondary outcomes included re-excision rates and time to adjuvant therapy.RESULTS: Overall, 880 patients underwent 899 therapeutic mammaplasty procedures at 50 centres. The most common indications were avoidance of poor cosmetic outcomes associated with standard breast-conserving surgery (702 procedures, 78·1 per cent) or avoidance of mastectomy (379, 42·2 per cent). Wise-pattern skin incisions were the most common (429 of 899, 47·7 per cent), but a range of incisions and nipple-areola pedicles were used. Immediate contralateral symmetrization was performed in one-third of cases (284 of 880, 32·3 per cent). In total, 205 patients (23·3 per cent) developed a complication, but only 25 (2·8 per cent) required reoperation. Median postoperative lesion size was 24·5 (i.q.r. 16-38) mm. Incomplete excision was seen in 132 procedures (14·7 per cent), but completion mastectomy was required for only 51 lesions (5·7 per cent). Median time to adjuvant therapy was 54 (i.q.r. 42-66) days.CONCLUSION: Therapeutic mammaplasty is a safe and effective alternative to mastectomy or standard breast-conserving surgery. Further work is required to explore the impact of the technique on quality of life, and to establish cost-effectiveness.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Breast Neoplasms/surgery

KW - Carcinoma, Ductal, Breast/surgery

KW - Clinical Decision-Making

KW - Female

KW - Humans

KW - Italy

KW - Mammaplasty/methods

KW - Mastectomy/methods

KW - Middle Aged

KW - Patient Care Planning

KW - Patient Readmission/statistics & numerical data

KW - Perforator Flap/statistics & numerical data

KW - Postoperative Complications/etiology

KW - Practice Patterns, Physicians'/statistics & numerical data

KW - Preoperative Care

KW - Prospective Studies

KW - Reoperation/statistics & numerical data

KW - Treatment Outcome

KW - United Kingdom

KW - Young Adult

U2 - 10.1002/bjs.10959

DO - 10.1002/bjs.10959

M3 - Article

C2 - 30132807

VL - 105

SP - 1778

EP - 1792

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 13

ER -